Liberation from Renal Replacement Therapy in Acute Kidney Injury patients: The current routine and insights into the future
The decision to stop RRT is a critical step that necessitates careful consideration of various clinical parameters. Currently, the liberation rocess is informed by changes in traditional kidney function markers, such as serum creatinine and urine output, in conjunction with the patient's clinical status.
SphingoTec has discovered Proenkephalin A 119-159 (penKid), a biomarker with a strong body of evidence on its relevance and added value to the AKI diagnosis augmented by its strong performance in the clinical routine.
In this interview, Prof. Peter Pickkers (Radboud University Medical Center, Nijmegen) highlights the research background on the novel kidney function biomarker Proenkephalin A 119-159, including a new formula for the glomerular filtration rate (GFR) based on this biomarker.
Acute kidney injury (AKI) is featured by acute deterioration in renal function, defined by changes in serum creatinine (SCr), urine output, or both. As one syndrome, AKI encompasses a wide variety of causes and risk factors, leading to a decline in kidney function or renal damage.